Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Discovery
Cancer Discovery
  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

Research Watch

Epigenetic Silencing of TH1-Type Chemokines Promotes Tumor Immune Evasion

DOI: 10.1158/2159-8290.CD-RW2015-209 Published December 2015
  • Article
  • Info & Metrics
  • PDF
Loading
  • Major finding: EZH2 and DNMT1 block production of TH1-type chemokines, enhancing tumor immune evasion.

  • Clinical relevance: High levels of EZH2 and DNMT1 are associated with reduced survival in patients with ovarian cancer.

  • Impact: Epigenetic reprogramming may improve the efficacy of tumor immunotherapies by blocking immune evasion.

Enhancer of zeste homologue 2 (EZH2) and DNA methyltransferase 1 (DNMT1) are often involved in the epigenetic silencing of genes in tumorigenesis; however, their roles in cancer immunotherapy are not understood. Peng and colleagues demonstrated that epigenetic silencing of immune-protective genes in cancer can promote tumor progression and reduce immunotherapy response. Combined inhibition of EZH2 (with DZNep) and DNMT (with 5-AZA-dC) in an ovarian cancer mouse model led to reduced tumor size, increased infiltration of T cells, elevated expression of TH1-type chemokines, and enhanced efficacy of programmed death ligand 1 (PD-L1) blockade and adoptive T-cell therapy. Knockdown or inhibition of EZH2 resulted in increased tumor cell expression of the TH1-type chemokine ligands CXCL9 and CXCL10 and augmented CD8+ T-cell infiltration in human ovarian cancer cells. Mechanistically, chromatin immunoprecipitation experiments revealed that DZNep treatment and EZH2 knockdown reduced trimethylation of lysine 27 of histone 3 (H3K27me3) on the CXCL9 and CXCL10 gene promoters, resulting in decreased expression. Consistent with this finding, microarray experiments in primary ovarian cancer cells identified 20 genes that exhibited altered expression in response to both EZH2 knockdown and GSK126 treatment, including CXCL9 and CXCL10. Additionally, knockdown of DNMT1 or treatment with 5-AZA-dC enhanced CXCL9 and CXCL10 expression, and bisulfite sequencing indicated that 5-AZA-dC treatment reduced CXCL10 DNA methylation, further suggesting that both H3K27me3 and DNA methylation repress the expression of TH1-type chemokines in ovarian cancer. In human ovarian cancer tissues, high expression of EZH2 and DNMT1 was associated with reduced overall survival and fewer intratumoral CD8+ T cells. These findings provide a mechanism to explain why some tumors are inflamed with T cells while others not. The results indicate that epigenetic silencing of TH1-type chemokines can promote immune evasion and tumor progression, and suggest that epigenetic reprogramming may improve the efficacy of cancer immunotherapy including checkpoint blockade and T-cell therapy.

Peng D, Kryczek I, Nagarsheth N, Zhao L, Wei S, Wang W, et al. Epigenetic silencing of TH1-type chemokines shapes tumor immunity and immunotherapy. Nature 2015;527:249–53.

Notes

Note: Research Watch is written by Cancer Discovery editorial staff. Readers are encouraged to consult the original articles for full details. For more Research Watch, visit Cancer Discovery online at http://cancerdiscovery.aacrjournals.org/content/early/by/section.

  • ©2015 American Association for Cancer Research.
PreviousNext
Back to top
Cancer Discovery: 5 (12)
December 2015
Volume 5, Issue 12
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Discovery article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Epigenetic Silencing of TH1-Type Chemokines Promotes Tumor Immune Evasion
(Your Name) has forwarded a page to you from Cancer Discovery
(Your Name) thought you would be interested in this article in Cancer Discovery.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Epigenetic Silencing of TH1-Type Chemokines Promotes Tumor Immune Evasion
Cancer Discov December 1 2015 (5) (12) 1237; DOI: 10.1158/2159-8290.CD-RW2015-209

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Epigenetic Silencing of TH1-Type Chemokines Promotes Tumor Immune Evasion
Cancer Discov December 1 2015 (5) (12) 1237; DOI: 10.1158/2159-8290.CD-RW2015-209
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Notes
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

Research Watch

  • Structures Identify Selpercatinib and Pralsetinib Resistance Mechanisms
  • Cryo-EM Structures Reveal Mechanism of Anticancer MCT1 Inhibitors
  • Computational Tool Characterizes Previously Unidentified Tumor Subtypes
Show more Research Watch

Epigenetics

  • Computational Tool Characterizes Previously Unidentified Tumor Subtypes
  • FBXO44 Silences Repetitive Elements during DNA Replication in Cancer
  • H1 Loss Increases Accessibility of Stemness Genes to Drive Lymphoma
Show more Epigenetics
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • OnlineFirst
  • Current Issue
  • Past Issues

Info For

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Discovery

  • About the Journal
  • Editors
  • Journal Sections
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Discovery
eISSN: 2159-8290
ISSN: 2159-8274

Advertisement